Now Playing
News|Videos|December 19, 2023
Diagnosing Blastic Plasmacytoid Dendritic Cell Neoplasm
Author(s)Sangeetha Venugopal, MD, MS
Sangeetha Venugopal, MD, MS, provides an overview of how patients with blastic plasmacytoid dendritic cell neoplasms (BPDCN) are diagnosed.
Advertisement
Episodes in this series
Advertisement
Related to this article
Five-year outcomes from neoadjuvant, adjuvant, and perioperative immunotherapy trials in resectable NSCLC clarify which patients benefit most.
A collaborative research initiative will unite two comprehensive inflammatory breast cancer clinics.
Ris-rez improved PFS vs chemotherapy in the ARTEMIS-011 trial for relapsed/refractory osteosarcoma.
Sanja Dacic, MD, PhD, outlines advances that are reshaping molecular profiling in advanced non–small cell lung cancer and how to navigate these changes.
Solange Peters, MD, PhD, outlines why docetaxel still anchors second-line therapy in NSCLC and where biomarker retesting could move the field.
Phase 3 BOND-003 cohort C findings showed a 75.5% CR rate and durable bladder preservation in high-risk, BCG-unresponsive NMIBC.
The FDA issued final guidances on performance status, washout periods, and laboratory values aimed at expanding oncology trial participation.
Laurence J. DiNardo, MD, FACS, discusses ctDNA testing in head and neck cancers, advancements in targeted therapies, and multidisciplinary collaboration.
Advertisement
Advertisement
Trending on OncLive
1
FDA Finalizes 3 Guidance Documents to Broaden Cancer Clinical Trial Eligibility Criteria
2
HR-Positive/HER2-Negative Metastatic Breast Cancer: Treatment Sequencing After Adjuvant Endocrine Therapy and Transitioning Beyond Endocrine-Based Approaches
3
Docetaxel Remains Unbeaten in Immunotherapy-Refractory NSCLC
4
Ris-Rez Meets Phase 3 Efficacy End Point for R/R Osteosarcoma
5